Atriva receives seed financing to develop its next generation influenza therapeutic
The next generation of Antiviral Therapies: Led by Stichting Participatie Atriva together with High-Tech Gründerfonds (HTGF), Atriva Therapeutics GmbH has received seed financing from Dutch and German private investors to advance Atriva’s antiviral MEK-Inhibitors (Mitogen-activated protein kinase kinase inhibitor) against Influenza into the clinical development stage.
Atriva Therapeutics Announces Upcoming US Patent Issuance for MEK Treatment against Viral Diseases
Tübingen, Germany, November 04, 2016 -- Atriva Therapeutics GmbH announces that the USPTO issued the Notice of allowance meaning that grant of one of its core patents: “MEK Inhibitors in the treatment of virus diseases” (US Application 14/434,328) is intended.
Atriva Therapeutics completes transfer of Co-Infection Patent
June 30th, 2016, Tübingen, Germany
Atriva Therapeutics GmbH announces the acquisition of the co-infection patent (Application Nr: PCT/IB2015/053644) from the University of Muenster, Germany.
ATRIVA Therapeutics Gewinner des S4L Venture Cups 2016
In Berlin wurden Anfang März die Gewinner der Konzeptphase des Science4Life Venture Cups gekürt.
Read more ...